2,2'-Oxybis-3-buten-1-OL | 83682-68-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2'-Oxybis-3-buten-1-OL
• 英文别名: 2-(1-hydroxybut-3-en-2-yloxy)but-3-en-1-ol
• CAS: 83682-68-2
• 化学式: C₈H₁₄O₃
• 分子量: 158.19
• InChiKey: SWGZKVFKQNDMET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR<br/>[FR] COMPOSITIONS COMPORTANT UN INHIBITEUR DE LA PROTEASE DU VIH
  申请人：PFIZER

  公开号：WO2005056542A1

  公开（公告）日：2005-06-23

  The present invention relates to pharmaceutical compositions comprising amorphous (4R)-N-allyl-3-(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in the manufacture of a medicament for the treatment HIV-infected mammals, such as humans.

  本发明涉及包含非晶态(4R)-N-烯丙基-3-(2S,3S)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-苯基丁酰}-5,5-二甲基-1,3-噻唑烷-4-羧酰胺，或其药学上可接受的盐或溶剂的制药组合物，其制备方法，其在抑制HIV蛋白酶酶的用途，以及其在制造用于治疗HIV感染哺乳动物，如人类的药物中的用途。
• Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
  申请人：XenoPort, Inc.

  公开号：US20140056973A1

  公开（公告）日：2014-02-27

  Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.

  口服剂型和颗粒制剂中含有高含量的甲基氢富马酸前药。
• Compositions comprising an HIV protease inhibitor
  申请人：Smith Wendell Scott

  公开号：US20050129772A1

  公开（公告）日：2005-06-16

  The present invention relates to pharmaceutical compositions comprising amorphous (4R)—N-allyl-3-(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in treating HIV-infected mammals, such as humans.

  本发明涉及制药组合物，包括非晶态(4R)-N-烯丙基-3-(2S,3S)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-苯基丁酰}-5,5-二甲基-1,3-噻唑烷-4-羧酰胺或其药学上可接受的盐或溶剂，它们的制备方法，它们在抑制HIV蛋白酶酶中的使用以及它们在治疗HIV感染的哺乳动物，例如人类中的使用。
• Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
  申请人：Pfizer Products Inc.

  公开号：EP1961419A1

  公开（公告）日：2008-08-27

  The present invention relates to a unitary dosage form comprising: (a) a solid amorphous dispersion comprising a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer; and (b) an HMG-CoA reductase inhibitor; wherein said concentration-enhancing polymer is a neutralized acidic polymer in which at least 90% of the acidic moieties have been neutralized.

  本发明涉及一种单一剂型，包括：(a) 由胆固醇酯转移蛋白抑制剂和浓度增强聚合物组成的固体无定形分散体；以及 (b) HMG-CoA 还原酶抑制剂；其中所述浓度增强聚合物是一种中和酸性聚合物，其中至少 90% 的酸性分子已被中和。
• Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
  申请人：XENOPORT, INC.

  公开号：US10716760B2

  公开（公告）日：2020-07-21

  Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.

  公开了富马酸氢甲酯及其原药的改进口服剂型。还公开了使用此类剂型治疗多发性硬化症和牛皮癣等疾病的方法。